This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Good morning, everyone. Thanks for joining us. I'm Canaccord Genuity Senior Biotech Analyst, Ritu Baral, and thank you for joining us for the Avanir presentation. With us this morning to present is CEO, Keith Katkin.
As many of you know, Avanir has launched and is rolling out NUEDEXTA for pseudobulbar affect, a condition that affects many patients with neurodegenerative diseases such as stroke, traumatic brain injury and Alzheimer’s
Before we begin, I would just point you to the disclosures in your conference materials for the relationship between Canaccord on the banking front but without further ado, here's Keith.
Thanks, Ritu, and good morning, everyone. Thank you for joining us for the Avanir Incorporate presentation. I'd like to start with the forward-looking statement as I will be making statements that are forward-looking in nature. I would encourage everyone to look at our quarterly and annual filings available on either the SEC website or the Avanir website.
Avanir is a uniquely positioned specialty biopharmaceutical company focused on CNS therapies and I say uniquely positioned because we have accomplished arguably one of the more difficult aspects of a pharmaceutical company which is obtaining FDA approval of our lead product candidate, NUEDEXTA.
We obtained FDA approval late in 2010 as the first and only FDA-approved therapy for the treatment of pseudobulbar affect and subsequently launched NUEDEXTA in February, 2011.